Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brown Adipose Tissue in ALS (BATALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03150290
Recruitment Status : Not yet recruiting
First Posted : May 12, 2017
Last Update Posted : May 12, 2017
Sponsor:
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary:
Weight loss is a common phenomenon in ALS. During the course of the disease, difficulty in swallowing and mastication can be responsible for a decrease in caloric intake and thus for weight loss. However, significant weight loss can also be observed in patients with no feeding difficulties. About half of ALS patients have an increase in their resting energy consumption, but the origin of this "hypermetabolism" remains unknown. "Brown" fat is specialized in the production of heat. Unlike "white" fat that stores excess caloric intakes, brown fat consumes energy. In humans, brown fat has long been considered as absent in adults. However, recent imaging techniques have been able to detect brown fat deposits in some adult subjects. The aim of this study is thus to determine the role of brown fat on energy consumption in Amyotrophic Lateral Sclerosis.

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Other: Indirect Calorimetry. Device: 18-FDG-PET Not Applicable

Detailed Description:

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder involving motor neurons of the cerebral cortex, brain stem and spinal cord. Motor neuron loss results in rapidly progressive muscle paralysis, usually leading to death from respiratory failure in 3-5 years.

Weight loss is a frequent phenomenon and an independent negative prognostic factor for survival in ALS. Involvement of bulbar muscles with dysphagia is likely to lead to decrease in energy intake resulting in negative energy balance. However, weight loss also occurs in non-dysphagic patients, and is not restricted to reduction in skeletal muscle mass but also involves fat mass reduction.

Hypermetabolism (i.e. elevation of resting energy expenditure, REE) have been reported in ALS in about 50% of ALS patients but the origin of this hypermetabolism remains unknown. Increase of REE seems paradoxical in the context of ALS because skeletal muscle mass, which accounts for a large proportion of energy consumption and heat production, is decreased in ALS patients. Brown adipose tissue (BAT) is another important organ for basal and inducible energy expenditure and thermogenesis. In humans, BAT is primarily found in infants and young children, and healthy adults has long been considered as almost devoid of functional BAT. However, a recent study using 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomographic (PET) scan showed that depots of functional BAT were present in about 5% of adult humans, most commonly localized in the cervical-supraclavicular region. In an autopsy series, depots of BAT in the periadrenal region were found in 19/20 ALS patients. It has been estimated that, if present, 50 g of maximally stimulated brown tissue could represent up to 20% of REE expenditure in an adult human. The presence of substantial, functional, depots of BAT could thus participate in the increase of REE observed in ALS patients.

The primary objective of this study is to identify and quantify potential depots of functional BAT in ALS patients. Secondary objectives will be to correlate amount of detectable BAT with measured REE, clinical parameters evaluating ALS progression and biological parameters.

This study will include 5 patients referred to the Paris ALS center with a diagnosis of ALS and "unexplained" (i.e. not explained by severe dysphagia) loss of 5 percent or more of normal body weight in the last 6 months. 5 ALS patients without significant weight loss will also be included in the study as controls.

For each patient, measurement of REE will be performed by indirect calorimetry. The volume and activity of BAT will be determined using 18F-FDG PET whole body scans. Data on concomitant and past disorders (including cancer and diabete mellitus), smoking history, medication use, height, current and normal body weight, age and site of onset of ALS symptoms will be recorded. Functional motor impairment will be assessed using manual muscle testing and the revised ALS Functional Rating Scale as in routine clinical practice.

This study will be the first to investigate, using non-invasive procedures, the role of depots of functional BAT in ALS patients' metabolic dysfunction. The results will provide new insights on the origin and consequences of the dysregulation of metabolic homeostasis in ALS.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Energy Expenditure and Brown Adipose Tissue in Amyotrophic Lateral Sclerosis
Estimated Study Start Date : June 2017
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2018


Arm Intervention/treatment
ALS patients without weight loss.
18-FDG-PET. Indirect Calorimetry.
Other: Indirect Calorimetry.
REE measurement

Device: 18-FDG-PET
18-FDG-PET

ALS patients with weight loss.
18-FDG-PET. Indirect Calorimetry.
Other: Indirect Calorimetry.
REE measurement

Device: 18-FDG-PET
18-FDG-PET




Primary Outcome Measures :
  1. Quantification of depots of functional brown adipose tissue in ALS patients (grams) [ Time Frame: performed at the first visit (1 day) ]
    measured by 18F-FDG-PET



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

10 ALS patients, fulfilling the following inclusion criteria:

  • Aged 18 to 85 (inclusive)
  • Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria
  • With unexplained significant loss of weight of 5 percent (or more) of normal body weight in the last 6 months (n=5 subjects) Or - without weight loss (n= 5 subjects)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03150290


Locations
Layout table for location information
France
Paris Als Center, Salpetriere Hospital Not yet recruiting
Paris, France, 75013
Contact: GAELLE BRUNETEAU, MD, PhD         
Contact    +33142162472    gaelle.bruneteau@aphp.fr   
Sponsors and Collaborators
Institut National de la Santé Et de la Recherche Médicale, France

Layout table for additonal information
Responsible Party: Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier: NCT03150290     History of Changes
Other Study ID Numbers: C16-83
2016-A01790-51 ( Registry Identifier: RCB )
First Posted: May 12, 2017    Key Record Dates
Last Update Posted: May 12, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Fluorodeoxyglucose F18
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action